Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调,获得FDA孤儿药称号

2019-10-20 不详 MedSci原创m

西班牙Minoryx Therapeutics公司宣布其候选药物来瑞格列酮(MIN-102)治疗Friedreich共济失调已被美国食品和药物管理局(FDA)授予孤儿药称号。

西班牙Minoryx Therapeutics公司宣布其候选药物来瑞格列酮(MIN-102)治疗Friedreich共济失调已被美国食品和药物管理局(FDA)授予孤儿药称号。

Friedreich共济失调是一种严重、罕见的遗传性神经退行性疾病,其特征是失去协调性和肌肉力量。该疾病是由于frataxin缺乏导致线粒体功能障碍所致。目前的患者仅依靠对症治疗来控制他们的疾病。

Leriglitazone(MIN-102)是一种新型、脑渗透性、口服可生物利用的选择性PPARγ激动剂,可与中枢神经系统内的目标受体结合。在多种临床前中枢神经系统疾病模型中证实了来瑞格列酮具有改善疾病的潜力,其具有抗氧化、抗炎和神经保护作用。Leriglitazone改善线粒体功能和生物发生,促进髓鞘再生,改善脂质代谢并延缓神经功能障碍的发展。来瑞格列酮目前处于肾上腺皮质神经疾病和弗里德里希共济失调的后期临床开发中。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]
    2019-10-22 diushouji
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958336, encodeId=e34119583362f, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat May 09 17:02:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365218, encodeId=a5331365218ff, content=<a href='/topic/show?id=dfa045434e1' target=_blank style='color:#2F92EE;'>#孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45434, encryptionId=dfa045434e1, topicName=孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379831, encodeId=ce0813e983191, content=<a href='/topic/show?id=72fee303d6' target=_blank style='color:#2F92EE;'>#FDA孤儿药称号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7303, encryptionId=72fee303d6, topicName=FDA孤儿药称号)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebe466, createdName=mxj1971612, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459701, encodeId=984e1459e0178, content=<a href='/topic/show?id=7dc3615626b' target=_blank style='color:#2F92EE;'>#来瑞格列酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61562, encryptionId=7dc3615626b, topicName=来瑞格列酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43a6186958, createdName=songbq, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627800, encodeId=3d53162e80039, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Tue Oct 22 09:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=)]